Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi, AI Startup Tie Up to Develop Influenza Diagnostic Device
May 8, 2019
- Japan Generic Market to Reach 1.2 Trillion Yen by 2022, Biosimilars, AG Market to Expand Too: Fuji Keizai
May 7, 2019
- Daiichi Sankyo Skips Pre-Verification for Vaccine Sterility Test, No Safety Concerns Found
May 7, 2019
- Boehringer Workforce Dwindles by 500 in Japan, MSD by 300: Jiho Survey
May 7, 2019
- Dupixent Now Available for Self-Injection
May 7, 2019
- Daiichi Sankyo Exercises Option to Commercialize Bispecific Antibodies Based on Joint Research with Zymeworks
May 7, 2019
- After Biogen Pullout, Salix Picks Up Rights to Mitsubishi Tanabe’s MT-1303
May 7, 2019
- Dupixent Filed for Sinusitis in Japan: Sanofi
May 7, 2019
- Astellas Looks to Fortify China Biz via Global Commercial Rejig
April 26, 2019
- Astellas’ Net Profit Soars 35% on Xtandi, Betanis
April 26, 2019
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
- Daiichi Sankyo to Move Up Japan Filing of DS-8201 to FY2019 H2
April 26, 2019
- CSL Behring Seeks Additional Indication for Privigen
April 26, 2019
- Ninlaro Filed in Japan for Post-Transplant Maintenance: Takeda
April 26, 2019
- Takeda Files Japan NDA for Cabozantinib, Exelixis’ RCC Treatment
April 26, 2019
- Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
- Takeda Cuts FY2018 Profit Outlook on Shire Takeover
April 26, 2019
- Delgocitinib Shows Good PIII Results in Pediatric Atopic Dermatitis: JT, Torii
April 26, 2019
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
- Daiichi Sells Nihonbashi Building to Raise Funds for Oncology R&D
April 26, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…